Quantitative approaches to 18F-flurpiridaz positron emission tomography image analysis
: Packard, René R. Sevag; deKemp, Robert A.; Knuuti, Juhani; Moody, Jonathan B.; Renaud, Jennifer M.; Saraste, Antti; Slomka, Piotr J.
Publisher: Elsevier BV
: NEW YORK
: 2025
: Journal of Nuclear Cardiology
: Journal of Nuclear Cardiology
: J NUCL CARDIOL
: 102180
: 45
: 16
: 1071-3581
: 1532-6551
DOI: https://doi.org/10.1016/j.nuclcard.2025.102180
: https://doi.org/10.1016/j.nuclcard.2025.102180
: https://research.utu.fi/converis/portal/detail/Publication/491896178
Key points
18F-flurpiridaz is a positron emission tomography (PET) radiotracer for myocardial perfusion imaging (MPI) approved by the United States Food and Drug Administration in September 2024.
This radiotracer's properties, including a very high 94% myocardial first-pass extraction fraction and positron range of 1 mm, render this probe suitable for high-resolution MPI and quantitative myocardial blood flow (MBF) determination.
We present 18F-flurpiridaz in the context of other PET MPI radiopharmaceuticals, discuss pivotal experimental studies that provided the foundation for subsequent software-based quantitative strategies in humans, and detail the published methods of relative MPI as well as MBF quantitation.
The reviewed methods provide a standardization of 18F-flurpiridaz PET and MBF interpretation that are poised to facilitate this radiotracer's adoption and implementation in cardiac imaging centers.
:
None.
